Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XERS

Xeris Biopharma Holdings Inc

Mar 27 • 04:00PM ET

5.63

Dollar change -0.08
Percentage change -1.40	%

Healthcare • Biotechnology • USA • NASD

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: IWM VTI VXF IWO VTWO IWC XPH ITOT FESM PSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	7.76%	Shs Outstand	149.43M	Perf Week	3.68%
Market Cap	866.68M	Forward P/E	46.43	EPS next Y	0.12	Insider Trans	-0.33%	Shs Float	142.00M	Perf Month	48.94%
Income	-54.84M	PEG	-	EPS next Q	-0.05	Inst Own	42.81%	Short Float	7.89%	Perf Quarter	64.62%
Sales	203.07M	P/S	4.27	EPS this Y	83.57%	Inst Trans	1.82%	Short Ratio	4.54	Perf Half Y	99.65%
Book/sh	-0.20	P/B	-	EPS next Y	299.45%	ROA	-16.37%	Short Interest	11.21M	Perf Year	166.82%
Cash/sh	0.47	P/C	12.10	EPS next 5Y	-	ROE	-617.16%	52W Range	1.69 - 6.07	Perf YTD	66.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.01%	ROI	-24.85%	52W High	-7.25%	Beta	1.13
Dividend TTM	-	Quick Ratio	1.19	Sales past 5Y	197.66%	Gross Margin	76.52%	52W Low	233.14%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	1.67	EPS Y/Y TTM	16.86%	Oper. Margin	-16.57%	RSI (14)	73.67	Volatility	6.26% 6.76%
Employees	394	Debt/Eq	-	Sales Y/Y TTM	23.89%	Profit Margin	-27.00%	Recom	1.33	Target Price	6.25
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	64.60%	Payout	-	Rel Volume	1.30	Prev Close	5.71
Sales Surprise	-1.90%	EPS Surprise	46.24%	Sales Q/Q	35.39%	Earnings	Mar 06 BMO	Avg Volume	2.47M	Price	5.63
SMA20	16.78%	SMA50	38.04%	SMA200	78.15%	Trades		Volume	3,205,304	Change	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Today 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
09:30AM	Loading…
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
07:00AM	Loading…
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
07:00AM	Loading…
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events (Business Wire)
May-06-24 07:42AM	Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product (MT Newswires)
07:00AM	Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics (Business Wire)
May-02-24 07:00AM	Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) +6.29%
Apr-03-24 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 07:00AM	Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-07-24 01:47PM	Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
11:56AM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 11:16PM	Q4 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -19.48%
12:52PM	XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:17AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:02AM	Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events (Business Wire)
07:00AM	Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital (Business Wire)
Mar-05-24 09:42AM	Why Xeris (XERS) Might Surprise This Earnings Season (Zacks)
Feb-28-24 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 (Business Wire)
Feb-05-24 07:00AM	Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference (Business Wire)
Jan-11-24 08:30AM	Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza (Zacks)
Jan-10-24 08:00AM	Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab (Business Wire) +16.18%
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
Jan-05-24 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 07:00AM	Xeris Biopharma Updates Its Outlook for 2023 (Business Wire) +12.95%
Dec-27-23 07:00AM	Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-23-23 07:32PM	11 High Growth Micro-Cap Stocks to Buy (Insider Monkey)
Dec-20-23 02:00PM	My Top Small-Cap Stock Pick for 2024 Is a Biotech With a Big Opportunity (TheStreet.com)
Nov-17-23 01:07PM	Xeris Biopharma CEO unveils game-changing drug innovations and record financial success (News Direct) +12.74%
Nov-10-23 04:00PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.65%
01:53AM	Q3 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 11:30AM	I've Prescribed Myself This Biotech Stock to Get Through the Market Mess (TheStreet.com) -8.84%
08:10AM	Xeris Biopharma Holdings Inc (XERS) Reports Substantial Revenue Growth in Q3 2023 (GuruFocus.com)
07:17AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 06:15PM	Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates (Zacks)
Oct-16-23 07:00AM	Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023 (Business Wire) +20.25%
Sep-27-23 08:00AM	Xeris Biopharma Announces Private Convertible Note Exchange Transactions (Business Wire)
Sep-20-23 07:36AM	Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Sep-14-23 04:05PM	Xeris to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire)
Aug-28-23 07:00AM	Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) +5.58%
Aug-17-23 11:00AM	Why I Bought Google Stock Today (TheStreet.com)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Aug-10-23 11:59AM	Xeris Biopharma CEO unveils record quarterly revenue, underpinned by unique business model (News Direct)
Aug-08-23 12:05PM	I Like This Small-Cap Stock Long-Term: This Is How I'll Trade It (TheStreet.com)
09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
07:13AM	Xeris Biopharma: Q2 Earnings Snapshot (AP Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 07:00AM	Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023 (Business Wire)
Jul-31-23 07:00AM	Xeris Ships One Millionth Gvoke® Unit (Business Wire)
Jun-29-23 04:19PM	Xeris Biopharma CEO reveals impact of CSO's departure and exciting future plans (News Direct) -10.98% +11.49%
Jun-22-23 01:50PM	Xeris Biopharma reaches Phase 2 milestone by dosing first participant in hypothyroidism study (News Direct)
Jun-21-23 07:00AM	Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism (Business Wire)
Jun-19-23 12:58PM	Xeris Pharmaceuticals shares latest product and partnership updates (News Direct)
Jun-01-23 07:00AM	Xeris Biopharma to Participate at the Jefferies Healthcare Conference (Business Wire)
May-09-23 11:33PM	Q1 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) +13.75% +7.33%
07:25AM	Xeris Biopharma: Q1 Earnings Snapshot (AP Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2023 Financial Results (Business Wire)
May-08-23 06:37AM	Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are individual investors with 56% stake, while 33% is held by institutions (Simply Wall St.)
May-02-23 07:00AM	Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 (Business Wire)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hecht Beth	See Remarks	Mar 20 '25	Sale	5.43	40,000	217,244	1,353,510	Mar 21 05:31 PM
Hecht Beth	Officer	Mar 20 '25	Proposed Sale	5.14	40,000	205,600		Mar 20 05:26 PM
Pieper Steven	See Remarks	Nov 22 '24	Option Exercise	1.55	19,483	30,199	1,441,820	Nov 26 05:00 PM
Schmid John P.	Director	Aug 12 '24	Buy	2.25	4,515	10,147	25,200	Aug 13 04:15 PM
Schmid John P.	Director	Aug 09 '24	Buy	2.37	4,285	10,134	20,685	Aug 12 06:28 PM
Schmid John P.	Director	May 10 '24	Buy	1.91	5,400	10,314	16,400	May 10 04:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XERS

Xeris Biopharma Holdings Inc

Upgrade your FINVIZ experience